TG Therapeutics (NASDAQ:TGTX) Now Covered by TD Cowen

TD Cowen initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research note published on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $50.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. B. Riley increased their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

TG Therapeutics Stock Up 5.6 %

Shares of TGTX stock opened at $25.71 on Tuesday. The company has a 50 day simple moving average of $23.44 and a two-hundred day simple moving average of $19.85. The stock has a market cap of $3.97 billion, a P/E ratio of 111.78 and a beta of 2.21. TG Therapeutics has a 12 month low of $6.98 and a 12 month high of $26.41. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s revenue for the quarter was up 357.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.34) EPS. On average, research analysts expect that TG Therapeutics will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in TG Therapeutics during the second quarter valued at $36,501,000. Hood River Capital Management LLC bought a new position in shares of TG Therapeutics during the 1st quarter valued at about $22,420,000. Point72 Asset Management L.P. purchased a new position in shares of TG Therapeutics during the second quarter valued at about $10,423,000. Assenagon Asset Management S.A. bought a new stake in shares of TG Therapeutics in the second quarter worth about $8,698,000. Finally, Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after buying an additional 199,770 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.